Skip to main content

Table 2 Subgroup analysis of the effects of isoflavones on serum total cholesterol. Isoflavones were shown to have significant benefits when given in the form of ISP or soy protein capsule. Regardless the forms of prescription, isoflavones decreased serum total cholesterol among normolipidemic but not hyperlipidemic subjects.

From: Effects of isoflavones (soy phyto-estrogens) on serum lipids: a meta-analysis of randomized controlled trials

Subgroup outcome

No. of comparisons

No. of subjects ||

Treatment effect on TC (mmol/L) ¶

Heterogeneity p-value §

Form of intervention †:

    

   a.) isoflavones tablets

12 [8–10, 12, 13, 16–18, 20, 21]

482

0.01 (-0.17, 0.18)

1.00

   b.) ISP(+)

8 [14, 15, 22, 23]

229

-0.11 (-0.21, -0.01)*

0.34

   c.) soy protein capsule

1 [11]

78

-0.69 (-1.19, -0.19)*

NA

   d.) soy biscuit

1 [7]

20

-0.05 (-0.47, 0.37)

NA

   e.) soy burger

1 [19]

44

0.09 (-0.38, 0.56)

NA

   f.) Overall

21 [7–23]

853

-0.09 (-0.18, -0.01)*

0.77

Isoflavones mixture ‡:

    

   G&D&B&F

5 [12, 13, 17, 18]

214

-0.06 (-0.34, 0.21)

0.96

   G&D

6 [9–11, 16, 19, 22]

285

-0.22 (-0.41, -0.03)*

0.06

   G

1 [21]

60

0.10 (-0.35, 0.55)

NA

Isoflavones intake (mg per day):

    

   < 50

3 [8, 13, 17]

132

-0.12 (-0.54, 0.29)

0.99

   51–100

12 [8, 10, 12, 14, 15, 17–23]

484

-0.10 (-0.21,0.01)

0.74

   101 – 150

4 [9, 11, 15, 23]

176

-0.10 (-0.24, 0.05)

0.09

Design :

    

   parallel crossover

9 [8–14, 21]

447

-0.08 (-0.27, 0.10)

0.48

a.) no washout

1 [22]

56

-0.43 (-0.73, -0.13)*

NA

b.) washout mentioned

6 [15, 19, 20, 23]

208

-0.07 (-0.17, 0.03)

0.91

Gender:

    

   male

2 [7, 22]

76

-0.30 (-0.54, -0.05)*

0.15

   female

17 [8–11, 13–18, 20, 21, 23]

674

-0.07 (-0.17, 0.02)

0.89

Treatment length:

    

   2–10 weeks

14[7, 10, 12, 13, 15–17, 19, 20, 22, 23]

541

-0.09 (-0.18, 0.00)

0.84

   11–20 weeks

3 [11, 14, 18]

155

-0.22 (-0.52, 0.07)

0.07

   21–30 weeks

4 [8, 9, 21]

157

0.02 (-0.28, 0.31)

0.96

Menopausal status:

    

   pre-menopausal

3 [15, 18]

80

-0.06 (-0.17, 0.06)

0.58

   peri-menopausal

1 [11]

78

-0.69 (-1.19, -0.19)*

NA

   post-menopausal

13 [8–10, 13, 14, 16, 17, 20, 21, 23]

516

-0.05 (-0.20, 0.10)

1.00

Subjects with:

    

   normolipidemia

8 [11, 12, 15, 18, 19, 21, 22]

377

-0.11 (-0.21, -0.01)*

0.08

   hyperlipidemia

3 [7, 9, 14]

105

-0.05 (-0.36, 0.26)

1.00

  1. * statistically significant † 'ISP (+)' = isoflavone containing isolated soy protein; 'ISP (-)' = isoflavone depleting isolated soy protein ‡ 'G' = Genistein; 'D' = Daidzein; 'B' = Biochanin A; 'F' = Formononectin § NA = not applicable || Since subjects acted as their own controls in a crossover trial, the 'calculated' total number was thus doubled in a single pair comparison. ¶ 95% confidence interval in parenthesis